Shots:

• The P-III COSMIC-311 trial evaluates Cabometyx (60mg- qd) vs PBO in a ratio (2:1) in 258 patients aged ≥12yrs. with previously treated radioactive iodine-refractory DTC across 164 sites globally
• An updated analysis showed ORR (11% vs 0%) as assessed by BIRC in ITT population including 1 CR- m-OS (19.4mos.) for Cabometyx but not estimable for PBO. The safety profile was consistent with previously observed- AEs were regulated with dose modifications- treatment discontinuation due to TEAEs (8.8% vs 0%)- grade 3/4 TEAEs (62% vs 28%)
• In Sept’17- 2021- the therapy has received the US FDA’s approval for LA or metastatic DTC patients that has progressed following prior VEGFR targeted therapy

| Ref: Exelixis | Image: wikipedia